Delirium – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Delirium Market Outlook

Thelansis’s “Delirium Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Delirium treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Delirium Overview

Delirium is a severe neuropsychiatric condition characterized by a sudden onset of attention deficits and cognitive impairments. Patients often exhibit varying levels of consciousness, ranging from reduced responsiveness akin to a near-coma state to heightened vigilance and extreme restlessness. Additionally, they may undergo distressing psychotic symptoms, including hallucinations, delusions, and mood alterations. The intensity and presence of delirium symptoms tend to fluctuate. This condition brings considerable distress to both patients and their caregivers. It arises from multiple potential triggers, such as acute medical illnesses, drug-related issues, withdrawal, trauma, or surgical procedures. While most causes originate outside the brain, instances of delirium stemming from primary neurological causes like strokes are acknowledged. The duration of delirium varies widely, with most episodes spanning a few days, although some cases persist for weeks or even months in about 20% of individuals. The term “subsyndromal delirium” describes patients who exhibit some features of delirium but do not meet all the diagnostic criteria. Several predisposing risk factors contribute to delirium, including advanced age, cognitive impairments like dementia, frailty, underlying health conditions such as cardiovascular and renal diseases, psychiatric disorders including depression, alcohol use, poor nutritional status, and sensory impairments like vision and hearing problems. Delirium manifests in three subtypes: hyperactive, hypoactive, and mixed. The hyperactive subtype presents with agitation, disorientation, delusions, and possible hallucinations. This appearance can be mistaken for schizophrenia, agitated dementia, or a psychotic disorder. The hypoactive subtype involves subdued confusion, disorientation, apathy, and quietness. In these cases, delirium might be overlooked or confused with depression or dementia. The mixed subtype showcases fluctuation between hyperactive and hypoactive features. Managing delirium symptoms may involve employing antipsychotic medications to control agitation and hallucinations and improve attention and orientation abilities (sensorium clearing).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Delirium – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034